Thyroid hormone regulates hepatic LDL receptor activity and influences LDL-C and ApoB levels.

Thyroid hormone serves as a primary regulator of lipid homeostasis, specifically through its control of low-density lipoprotein (LDL) metabolism. The relationship between thyroid signaling and serum cholesterol is driven by the hormone's direct influence on hepatic receptor activity and the subsequent clearance of atherogenic particles.

Mechanistic explanations

Thyroid hormone (specifically triiodothyronine, or T3) increases the expression and activity of hepatic LDL receptors (LDLR) through direct transcriptional regulation.

• Transcriptional Activation: T3 binds to the thyroid hormone receptor β1 (TRβ1), which heterodimerizes with the retinoid X receptor α (RXRα). This complex binds to specific thyroid hormone response elements (TREs) located within the LDLR promoter, initiating mRNA expression.
• SREBP-2 Synergy: The regulation of LDLR is further amplified by a synergistic interaction with Sterol Regulatory Element-Binding Protein-2 (SREBP-2). T3-bound receptors cooperate with SREBP-2 through protein-protein interactions or by binding to adjacent promoter sites. Additionally, T3 increases the abundance of mature SREBP-2, reinforcing the upregulation of cholesterol-clearing pathways.

Clinical and effectiveness evidence

Reduced thyroid signaling, characteristic of both overt and subclinical hypothyroidism, leads to a significant downregulation of LDLR. This impairment in receptor-mediated clearance causes a systemic accumulation of LDL cholesterol (LDL-C) and its structural protein, Apolipoprotein B (ApoB).

• Lipid Elevations: Observational data consistently show that patients with subclinical hypothyroidism have significantly higher LDL-C levels compared to euthyroid individuals.
• Treatment Reversibility: Systematic reviews and meta-analyses of randomized controlled trials demonstrate that thyroid hormone replacement therapy (levothyroxine) reverses these lipid elevations. Meta-analyses report highly significant reductions in ApoB (p < 0.00001) and LDL-C (p = 0.03) following treatment, particularly in older adults with subclinical hypothyroidism.

Bottom line

Thyroid hormone is essential for maintaining hepatic LDLR activity; reduced signaling directly impairs LDL clearance, leading to elevated LDL-C and ApoB. These elevations are typically reversible through thyroid hormone replacement therapy, which restores receptor-mediated lipid metabolism.